Kornimate/medical-research-clean huggingface dataset:
local warming of surgical incisions

Conditions: Surgical Wound Infection

Summary: the purpose of this study is to determine if local warming of surgical wounds improves healing and helps prevent infection. the investigators want to see if warming surgical incisions improves oxygen levels and healing in skin close to the incision.

surgical site infections (ssi) account for 37% of us hospital infections and increase morbidity and cost. high rates (10-22%) of ssi are associated with colorectal surgery and obesity. bacterial resistance requires oxygen and higher tissue oxygen limits infection in general surgery patients. control of core and local temperature may increase infection resistance by modulating perfusion, oxygenation, angiogenesis and immune cell responses. perioperative hypothermia reduces tissue oxygen while normothermia lowers ssi rates. warming injured tissues locally may offer additional benefit. warming incisions immediately after surgery and intermittently for two days after gastric bypass or colectomy surgery reduced infection rates in a pilot sample. systematic study of clinical outcomes and potential mechanisms in a larger study is lacking and is the focus of the current study.

Eligibility criteria:
inclusion criteria: * 18 and older, * scheduled for bariatric, colon or gynecological surgery, * able to speak and read english. exclusion criteria: * glucocorticoids greater than 5 mg per day, * albumin below 3.0, * creatinine above 2.5 mg/dl, * history of pulmonary edema.

Keywords: surgical site infection wound healing tissue oxygen angiogenesis flow cytometry immunohistochemistry
dendritic killer cell-based immunotherapy for solid tumors

Conditions: Colorectal Neoplasms; Hepatocellular Carcinoma; Neoplasm Metastasis

Summary: the primary objective of this study is to evaluate the safety of autologous dendritic killer cell (dkc) in patients with metastatic solid tumor and to evaluate the maximum tolerated dose (mtd) of dkc. the primary endpoint of safety evaluation includes physical examination, assessment of vital sign, laboratory test, concomitant medication, and adverse event (ae). the secondary endpoints regarding efficacy includes the generation of tumor specific immune response by detecting cd3+ cd8+ cd69+ ifn-gamma+ t cells, and the improvement of quality of life


Eligibility criteria:
inclusion criteria: 1. capable and willing of providing signed informed consent before study 2. patient age ≥20 at date of consent 3. performance status (ecog) ≤2 4. patients have a life expectancy of \> 3 months 5. patients agree to be in compliant to clinical protocol planned treatment plan 6. histologically confirmed metastatic solid tumor, including colon cancer, gastric cancer, pancreatic cancer, bile duct cancer, liver cancer 7. patient with histological and conventional imaging proven measurable lesion 8. patients not pregnant. all male and female patients with reproduction ability should use appropriate contraception method(s) during the study period 9. patient is not currently under immunosuppressive treatment for previous or recurred autoimmune disease 10. patient should have received and failed prior standard cancer therapies (according to tvgh standard cancer treatment procedures, or national comprehensive cancer network clinical practice guidelines in oncology) 11. patient with adequate hematology function: absolute neutrophil count (anc) ≥ 1,500 cells total white blood cell (wbc) ≥ 3,000 cells /mm3 hemoglobin ≥ 9 g/dl platelets ≥ 100,000 counts /mm3 12. patient with adequate hepatic and renal function serum creatinine ≤ 1.5x upper limit of normal (uln) total bilirubin (tb) ≤ 1.5x uln, or ≤ 2.5x uln for patients with primary hcc or liver metastasis alt and ast ≤ 2.5x uln, or ≤ 5x uln for patients with primary hcc or liver metastasis alkaline phosphatase (alp) ≤ 5x uln 13. patient showing negative response in syphilis, hiv, hbv and hcv test exclusion criteria: 1. any other investigational drug used within 28 days prior to first dkc administration 2. patient with known brain metastasis or metastasis to central nervous system 3. patient with pulmonary fibrosis 4. patient with pleural effusion or as cites correspond to ctcae grading \> 2 5. patient with uncontrolled disease including but not limit to cardiovascular disease, liver disease, renal disease or infectious disease 6. patients being diagnosed with any cognitive or psychiatric illness 7. patient not suitable to participate the trial for safety concerns as judged by the investigator

Keywords: clinical trial, phase i
carie care, chemomechanical caries removal technique in primary teeth

Conditions: Dental Caries; Primary Teeth

Summary: chemomechanical caries removal systems have emerged as a possible valuable alternative to conventional rotary caries removal techniques in pediatric patients. carie-care™ is an economically minimally invasive approach that selectively removes caries-infected tissue leaving the caries-affected tissue to conserve tooth structure


Eligibility criteria:
inclusion criteria: * open carious lesions with a moderately deep dentin carious lesion(scores five or six, according to the international caries detection and assessment system\[icdas\]. * the access of the carious lesion has to be large enough to allow the penetration of the excavator * children with behavior rating 3 or 4 according to the frankl scale exclusion criteria: * clinical or radiographic evidence of pulp, furcation, or periapical pathosis * proximal caries evidenced by bitewing x-ray
functional jejunal interposition improve nutritional status after total gastrectomy

Conditions: Gastric Cancer; Nutrition Disorders

Summary: the purpose of this study is to find out whether the nutritional status of patients undergoing functional jejunal interposition is better than those with roux-en-y after total gastrectomy for gastric cancer. to find a better reconstruction for patients who received total gastrectomy.

surgery is the only curative way for gastric cancer to date. methods of resection and reconstruction are closely related to prognosis and nutritional status. therefore, it is essential to choose. at present, more and more clinical centers tend to choose roux-en-y (ry) reconstruction after total gastrectomy, which are prone to a variety of complications, and seriously affects the quality of life, such as malnutrition. there is argument over whether functional jejunal interposition is better than those with roux-en-y after total gastrectomy for gastric cancer. how to improve the nutritional status of the patients following total gastrectomy with gastrointestinal reconstruction arouses people's attention. the purpose of this study was to evaluate differences of the nutritional status in patients undergoing functional jejunal interposition and roux-en-y after total gastrectomy.

Eligibility criteria:
inclusion criteria: * untreated patients with curative resectable gastric cancer (a)a clear pathological diagnosis (b)the surgeon and radiologist assess the possibility of removal (c)no previous history of other malignancies. (d)the patient has signed an informed consent form (e)cardiopulmonary and kidney function is normal (f)ecog body condition scores 0 to 1 (g)does not require emergency surgery exclusion criteria: - (a) pregnant or lactating women; (b) of the liver, lung, bone, and other distant metastasis; (c) positive supraclavicular lymph nodes, pelvic or ovarian species, peritoneal dissemination, etc.; (d) massive ascites, cachexia; (e) with other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, poor merger control hypertension, diabetes; (f) mental disorder or disease; (g) 4 weeks prior to enrollment participated or are participating in other clinical trials of patients; (h) had undergone surgery, and its influence has not been eliminated for patients; (i) a history of stomach or esophagus cancer, including stromal tumors, sarcoma, lymphoma, carcinoid; (j) combined with active infection in patients (infection caused by fever above 38 ℃); (k) in patients with poor compliance or poor patient compliance investigators to consider; (l) some researchers believe that other clinical, laboratory conditions patients should not participate in the trial.

Keywords: nutritional status functional jejunal interposition roux-en-y gastrectomy
an observational study of botox® for the management of urinary incontinence in patients with idiopathic overactive bladder

Conditions: Urinary Incontinence; Urinary Bladder, Overactive

Summary: this study will evaluate real world pattern of use of botox® in actual clinical practice in patients with idiopathic overactive bladder (ioab) with urinary incontinence whose symptoms have not been adequately managed by oral anticholinergic therapy.


Eligibility criteria:
inclusion criteria: * no prior treatment with botulinum toxin type a for treatment of ioab exclusion criteria: * treatment with any botulinum toxin type a within 18 months
beat-it: behavioural activation and severe learning disabilities

Conditions: Depression

Summary: depression is common, but no psychological interventions have been tested to see if they work for adults with severe intellectual disabilities. the research team recently successfully completed a full-scale trial of a psychological intervention, beatit, for depressed adults with mild/moderate intellectual disabilities. the aim of this study is to comprehensively evaluate the feasibility of modifying beatit for depressed adults with severe intellectual disabilities, collecting the information needed on likely recruitment, measures, and waiting list control arm options, to design a full-scale study.


Eligibility criteria:
inclusion criteria: * severe/profound intellectual disabilities * 18 years old and over * clinically significant unipolar depression * has a family member or paid carer who has supported them for a minimum of 6 months to complete the screening and baseline visits or is able to obtain information for the previous 4 months prior to randomisation. the carer, or another named individual, should be available for weekly-fortnightly treatment sessions with the practitioner, and should currently provide a minimum of 10 hours support per week to the participant. exclusion criteria: * suicidal * mild/moderate intellectual disabilities * factors that prevent the person from interacting with the carer and therapist or retaining information from the therapy (e.g. late stage dementia, significant agitation, withdrawal arising from psychosis) * does not consent to her/his gp being contacted about their participation in the study.

Keywords: intellectual disability
reduced iv fluids to improve clearance of hdmtx in children w/lymphoma or acute lymphoblastic leukemia

Conditions: Lymphoma; Acute Lymphoblastic Leukemia; Pediatric Cancer; Pediatric ALL; Pediatric Lymphoma

Summary: to determine whether a reduced volume hydration regimen will lead to a shorter time to methotrexate clearance when compared to a standard intravenous (iv) hydration regimen.

this study uses a prospective randomized controlled crossover study design. neither patients nor clinicians are blinded to the standard versus reduced intravenous fluids (ivf) regimen. patients are randomized to begin with standard volume or reduced volume ivf. over the course of 4 cycles of high dose methotrexate (hdmtx), patients alternate between standard and reduced volume post hydration fluids protocols.

Eligibility criteria:
inclusion criteria: * diagnosis of lymphoma or acute lymphoblastic leukemia * candidate for a minimum of 2 cycles hdmtx (5 g/m2) in the inpatient setting * creatinine clearance ≥ 65 ml/min by modified schwartz equation * patients of childbearing potential must have a negative pregnancy test (serum or urine) * lactating female patients must agree not to nurse a child while on this trial * all patients and/or their parents or legal guardians must provide written informed consent, with assent provided if applicable exclusion criteria: * trisomy 21 * history of dialysis within 30 days prior to study registration or currently on dialysis * polyuric renal dysfunction * pregnancy * known or suspected pleural effusion * medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements

Keywords: high dose methotrexate hdmtx intravenous fluids
nitrate and hypertension in heart transplanted patients

Conditions: Hypertension; Heart Transplantation

Summary: the aim of the study was to evaluate the acute effect of nitroglycerine infusion on blood pressure and heart rate in heart-transplanted patients with cyclosporine-induced hypertension.

background: cyclosporine represents a milestone in immunosuppression after organ transplantation. its use, however, comes at the cost of significant side effects, such as arterial hypertension. our aim was to investigate the effect of acute administration of nitroglycerin in heart-transplanted patients with cyclosporine-induced hypertension. methods: we included 18 hypertensive patients (ht) scheduled for elective cardiac catheterization after heart transplantation and treated with cyclosporine, as well as 6-matched ht. simultaneous measurements of bp in the aorta and pulmonary artery before and after administration of nitroglycerin were done. results: after injection of 50μg and 100μg nitroglycerin a significant bp decrease was observed both in heart-transplanted patients (sbp p=0.0001; dbp p=0.0001) and in controls (sbp p=0.006; dbp p=0.05). this reduction was more pronounced in heart-transplanted patients (sbp p=0.022; dbp 0.018 for group comparison). 8±3 minutes after the last nitrate infusion bp remained significantly reduced vs baseline in heart-transplanted patients (p\<0.001) while it comes back to baseline in controls. the reduction in sbp (p=0.04 after 50μg nitroglycerin; p=0.05 after 100μg nitroglycerin) but not dbp correlated to cyclosporinemia. conclusions: this study indicates that nitroglycerin reduces sbp in heart-transplanted patients with cyclosporine-induced hypertension. further studies are needed to evaluate the long-term effect of nitrates in these patients.

Eligibility criteria:
inclusion criteria: * heart-transplanted group: * patients with hypertension and treated with cyclosporine * patients under optimal standard therapy * patients giving written informed consent control group: * patients with hypertension * patients without prior transplantation of any kind * patients giving written informed consent exclusion criteria: * hypertensive patients receiving immunosuppressive drugs * patients receiving any kind or nitrate derivates

Keywords: heart transplantation cyclosporine hypertension nitroglycerin
polycystic ovary syndrome and urinary tract stones: a bmi-adjusted analysis in iraqi women

Conditions: PCOS (Polycystic Ovary Syndrome); Stone, Urinary; BMI; Obesity; Overweight; Underweight

Summary: the goal of this observational case-control study is to find out the impact of pcos as a risk factor for the presence of urinary tract stones taking into account the bmi of women aged 18-40 years consulting the gynecology and obstetrics outpatient clinic at al-elwiya maternity teaching hospital. the study aims to collect information from approximately 200 women with polycystic ovary syndrome and 200 volunteers who do not have pcos. a written consent was obtained from all the participants. the information collected included age, weight, and height. in addition, focused history and clinical examination were conducted for all patients, and for some patients, one or more additional blood tests were obtained. the additional tests included but not limited to serum levels of testosterone, dehydroepiandrosterone sulfate (dhea-s), androstenedione, luteinizing hormone (lh), follicle-stimulating hormone (fsh), and sex hormone-binding globulin. moreover, ultrasonography of the abdomen and pelvis was obtained for all patients as part of the diagnosis of pcos and as screening for urinary tract stones. also, transvaginal ultrasonography was obtained for some patients according to the individual condition as requested by the treating gynecologist. the diagnosis ofc pcos was based on the rotterdam criteria. (1) the main questions the study aims to answer are: * is pcos a risk factor for urinary tract stones when taking bmi into account? * is pcos a risk for urinary tract stones at all? * is there an association between pcos and bmi? * does bmi affect the presence of urinary tract stones at all and the presence of urinary tract stones when taking pcos into account?


Eligibility criteria:
inclusion criteria: * female * age 18-40 years exclusion criteria: * a medical or surgical condition that affects urinary tract stone formation. * a medical or surgical condition that affects body weight or height. * a medical or surgical condition that affects hormonal balance.

Keywords: pcos (polycystic ovary syndrome) stone, urinary bmi obesity overweight underweight
ibuprofen arginine and neural mobilization versus ibuprofen arginine in the treatment of carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: in the present investigation the pain reduction effects of a physiotherapy technique combined with pharmaceutical ibuprofen arginine treatment will be compared to those produced by ibuprofen (only) treatment, in subjects who suffer the signs and symptoms of carpal tunnel syndrome.

the present randomized clinical trial will perform a comparison of the pain reduction effects produced by the application of a non invasive and non pharmacological median nerve neural mobilization (physiotherapy treatment) combined with a pharmaceutical oral ibuprofen arginine treatment, to those effects produced by a ibuprofen arginine (only) treatment. additionally, effects over the functionality of the affected upper limb will be evaluated and compared. subjects will be invited to participate and randomly allocated to 2 different groups.

Eligibility criteria:
inclusion criteria: * participants must be medically diagnosed with unilateral carpal tunnel syndrome (with confirmative electrodiagnostic findings). * full understanding of written and spoken spanish (language). * participants must freely consent to participate. * the presence of positive phalen an tinel sings. * the presence of carpal tunnel syndrome signs and symptoms exclusion criteria: * the lack to meet inclusion criterions, the presence of cognitive impairment, tumors, cancer, recent (affected) upper limb surgery or trauma, pregnancy, kinesiophobia, deformities of the (affected) upper limb, recent skin injuries or infections (in the affected upper limb), autoimmune inflammatory conditions or flu type symptoms, allergy to gabapentin, allergy to ibuprofen arginine, and also: participants must not be (during the present investigation) under any type of pain reducing treatment (conservative, homeopathic, invasive or not invasive)

Keywords: ibuprofen arginine median nerve neural mobilization pain
immunogenicity of booster hepatitis b vaccines in children after liver transplantation

Conditions: Liver Transplantation; Hepatitis B

Summary: aim/background: this study aims to investigate the necessity and efficacy of a hepatitis b virus (hbv) vaccine booster in children after liver transplantation. a universal mass vaccination program of hbv was launched for 20 years in taiwan. the coverage rate is high and the effect is great. the carrier rate of the population under vaccine coverage decreased from 10-15% to \< 1%. in taiwan, most children who receive organ transplantation were vaccinated with hbv vaccine in infancy and well before the transplantation procedure. this vaccination background information on taiwanese children is quite unique and not similar to the other countries in the world. the antibody generated by the vaccine usually wanes after a certain period even in normal subjects, let alone in subjects who receive organ transplantation and immunosuppressive agents after transplantation. at present, taiwan is still an hbv hyperendemic area and the risk of exposure to hbv cannot be overlooked. should children be given a booster dose of hbv vaccine after transplantation? and how about the immunogenicity of this booster dose in these immunocompromised hosts? if these children cannot obtain an adequate antibody titer, will the risk of hbv infection increase? this study is designed to answer these questions. as a pediatric hepatologist, the author's routine work is to take care of children who underwent liver transplantation. to take advantage of this, the investigators decided to study the efficacy and necessity of hbv booster vaccine in these patients. however, the results of this study should be able to be applied to any kind of solid organ transplanted patients. method: the anti-hepatitis b surface antigen (hbs) titer will be checked in patients who received liver transplantation \> 1 year ago. if the titer is \< 10 iu/l, a booster dose will be administered. the humoral (anti-hbs) and cellular immunity (by elispot to assay t and b cell specific proliferation) and cytokine assay will be done in these patients before and after the booster dose. a three-year follow-up will be performed to monitor the hbv infection in these patients. expected results: the investigators expect for those who survive one year more after liver transplantation to yield a relatively good response to hbv booster under adequate immunosuppression.

the anti-hbs titer will be checked in the patients who received liver transplantation for \> 1 year. if the titer is \< 10 iu/l, a booster dose will be administered. the humoral (anti-hbs) and cellular immunity (by elispot to assay t and b cell specific proliferation) and cytokine assay will be done in these patients before and after the booster dose. a three-year follow-up will be performed to monitor the hbv infection in these patients.

Eligibility criteria:
inclusion criteria: * children who received liver transplantation \> 1 year ago exclusion criteria: * are now in an unstable condition

Keywords: hepatitis b virus vaccine booster liver transplantation